ArticleResearch square2026
Medical and Psychiatric Consultation for Patients Considering State-Regulated Psilocybin Services: A Risk-Reduction Model and Two Illustrative Cases.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Background: State-regulated psilocybin services have expanded access outside research settings. Patients seeking these services may have medical and psychiatric complexity not represented in clinical trials, while guidance for clinicians advising them remains limited. We introduce the Psilocybin Education and Assessment Collaborative for Excellence (PEACE), a consultation model within a traditional healthcare system developed to support patients considering Oregon Psilocybin Services (OPS). Methods: We describe the PEACE model's structure and clinical approach, including individualized assessment, evidence appraisal, education, risk-reduction planning, and care coordination. We present two longitudinal cases illustrating clinical complexity and outcomes after accessing OPS. Results: The first case involves a middle-aged man with alcohol use disorder who experienced early improvement after two OPS sessions and ultimately achieved abstinence through a nonlinear recovery process. During abstinence, he underwent a distressing high-dose unsupervised psilocybin experience, after which he received PEACE-supported integration care. The second case involves an older woman with major depressive disorder who completed supervised antidepressant tapers and underwent two supervised psilocybin experiences. Her depression worsened three months after the second experience, and she returned to PEACE for medication and integration support. Conclusion: These cases illustrate the challenges of extrapolating psychedelic clinical trial findings to real-world settings and the importance of longitudinal follow-up, as early improvement may not reflect longer-term, nonlinear recovery trajectories. Consultation models such as PEACE may support informed decision-making, risk reduction, continuity of care, and integration of psilocybin-related care into existing healthcare systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.